Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.4750 (-38.98%) ($8.4750 - $8.4750) on Thu. Jan. 27, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.04% (three month average) | RSI | 12 | Latest Price | $8.4750(-38.98%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -7.8% a day on average for past five trading days. | Weekly Trend | TGTX declines -12.8% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(75%) ARKG(69%) IBB(67%) ARKK(64%) IWO(62%) | Factors Impacting TGTX price | TGTX will decline at least -4.02% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-28%) UNG(-6%) USO(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.02% (StdDev 8.04%) | Hourly BBV | -1.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-15.79(-286.31%) | Resistance Level | $15.84 | 5 Day Moving Average | $13.04(-35.01%) | 10 Day Moving Average | $13.8(-38.59%) | 20 Day Moving Average | $15.84(-46.5%) | To recent high | -76.2% | To recent low | 0% | Market Cap | $1.073b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |